1222491-53-3

Basic information

• Product Name: tert-Butyl ((3R,6R)-rel-6-Methylpiperidin-3-yl)carbaMate
• Synonyms: tert-Butyl ((3R,6R)-rel-6-Methylpiperidin-3-yl)carbaMate;tert-butyl N-[trans-6-methylpiperidin-3-yl]carbamate;trans-tert-Butyl (6-methylpiperidin-3-yl)carbamate;Trans-Tert-Butyl (6-Methylpiperidin-3-Yl)Carbamate(WX601409)
• CAS NO: 1222491-53-3
• Molecular Formula: C11H22N2O2
• Molecular Weight: 214.30458
• Mol File: 1222491-53-3.mol
• Article Data: 16

Chemical Properties

• Boiling Point: 313.4±31.0 °C(Predicted)
• Appearance: /
• Density: 1.00±0.1 g/cm3(Predicted)
• PKA: 12.38±0.40(Predicted)
• CAS DataBase Reference: tert-Butyl ((3R,6R)-rel-6-Methylpiperidin-3-yl)carbaMate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-Butyl ((3R,6R)-rel-6-Methylpiperidin-3-yl)carbaMate(1222491-53-3)
• EPA Substance Registry System: tert-Butyl ((3R,6R)-rel-6-Methylpiperidin-3-yl)carbaMate(1222491-53-3)

Safety Data

• Hazardous Substances Data: 1222491-53-3(Hazardous Substances Data)

Usage

General Description

Tert-butyl ((3R,6R)-rel-6-Methylpiperidin-3-yl)carbamate is a chemical compound that belongs to the class of carbamate esters. It acts as a protective group for amines in organic synthesis, enhancing the selectivity of reactions by temporarily blocking certain functional groups. tert-Butyl ((3R,6R)-rel-6-Methylpiperidin-3-yl)carbaMate has a tert-butyl group, a carbamate group, and a (3R,6R)-rel-6-Methylpiperidin-3-yl group, which together contribute to its reactivity and stability. Tert-butyl ((3R,6R)-rel-6-Methylpiperidin-3-yl)carbamate is often used in pharmaceutical and agrochemical research, as well as in the development of new materials and compounds.

Upstream product

• 54751-93-8 6-methyl-3-piperidinol 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1150618-39-5 cis/trans-tert-butyl (6-methylpiperidin-3-yl)carbamate 
• 80287-53-2 5-Amino-2-methylpyridine 
• 323578-37-6 tert-butyl N-(6-methylpyridin-3-yl)carbamate 
• 1612786-30-7 (2R,5R)-benzyl 5-azido-2-methylpiperidine-1-carboxylate 
• 1431473-24-3 (2R,5S)-benzyl 5-hydroxy-2-methylpiperidine-1-carboxylate 
• 1612786-29-4 (2R,5S)-benzyl 2-methyl-5-((methylsulfonyl)oxy)piperidine-1-carboxylate 
• 1207853-22-2 (2R,5R)-benzyl-5-((tert-butoxycarbonyl)amino-2-methyl)piperidine-1-carboxylate 
• 1207853-72-2 benzyl (2R,5R)-5-amino-2-methyl-piperidine-1-carboxylate 
• 1207853-21-1 phenylmethyl (2S,5R)-5-({[(1,1-dimethylethyl)oxy]carbonyl}amino)-2-methyl-1-piperidinecarboxylate 
• 1227917-61-4 (3R,6S)-6-methyl-1-{[(phenylmethyl)oxy]carbonyl}-3-piperidinecarboxylic acid 
• 1227917-62-5 (3R,6S)-3-methyl 1-(phenylmethyl) 6-methyl-1,3-piperidinedicarboxylate 
• 5470-70-2 Methyl 6-methylnicotinate 

Downstream Products

• 1207853-22-2 (2R,5R)-benzyl-5-((tert-butoxycarbonyl)amino-2-methyl)piperidine-1-carboxylate 
• 1207853-21-1 phenylmethyl (2S,5R)-5-({[(1,1-dimethylethyl)oxy]carbonyl}amino)-2-methyl-1-piperidinecarboxylate 
• 1227916-43-9 C₂₂H₂₇FN₆O₂ 
• 1227917-65-8 C₂₂H₂₇FN₆O₂ 
• 1612786-54-5 (2-(2H-1,2,3-triazol-2-yl)phenyl)((2R,5R)-5-amino-2-methylpiperidin-1-yl)methanone 
• 1612786-14-7 2-(((3R,6R)-1-(2-(2H-1,2,3-triazol-2-yl)benzoyl)-6-methylpiperidin-3-yl)amino)isonicotinonitrile 
• 1612786-21-6 2-(((3R,6R)-1-(2-(2H-1,2,3-triazol-2-yl)benzoyl)-6-methylpiperidin-3-yl)(methyl)amino)isonicotinonitrile 
• 1612786-28-3 N-((3R,6R)-1-(2-(2H-1,2,3-triazol-2-yl)benzoyl)-6-methylpiperidin-3-yl)-N-(4-cyanopyridin-2-yl)acetamide 
• 1612786-33-0 tert-butyl ((3R,6R)-1-(2-(2H-1,2,3-triazol-2-yl)benzoyl)-6-methylpiperidin-3-yl)carbamate 
• 1405129-11-4 tert-butyl ((3S,6R)-1-(3-((2-(2,6-difluorophenyl)imidazo[1,5-b]pyridazin-7-yl)amino)pyridin-4-yl)-6-methylpiperidin-3-yl)carbamate 
• 1792180-81-4 1-[(2R,5R)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl]prop-2-en-1-one 
• 1792180-81-4 1-[(2S,5S)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl]prop-2-en-1-one 
• 1222491-53-3 1,1-dimethylethyl [6-methyl-3-piperidinyl]carbamate 
• 1792180-81-4 (-) 1-((2S,5R)-5-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one 

Relevant articles and documents

Preparation method of key intermediate of JAK3 enzyme inhibitor

The invention relates to a preparation method of a key intermediate ((3R,6S)-1-benzyl-6-methyl piperidine-3-amine) of a JAK3 enzyme inhibitor, and particularly relates to a method for preparing the required intermediate by taking 6-methyl piperidine-3-amine as an initial raw material through Boc protection, catalytic hydrogenation, benzyl protection, trifluoroacetic acid Boc de-protection, salt forming and splitting, and dissociation. The salt forming and splitting method comprises the following steps: mixing a racemic mixture containing a compound enantiomer with a structure shown in the formula with a splitting reagent with definite stereo-specificity in a solvent to form a solution, wherein the splitting agent is capable of binding at least one but not all of said enantiomers to form a precipitate containing the at least one the stereo-specific form of enantiomers; and collecting and purifying the precipitate , or collecting a solution containing other enantiomers and recrystallizing the enantiomers contained in the solution. The preparation method has the advantages of cheap and easily available raw materials, mild reaction conditions, high reaction controllability and good industrial application prospect.

PYRROLO [2,3-d] PYRIMIDINE TOSYLATE, CRYSTALLINE FORMS THEREOF, AND PREPARATION METHOD AND INTERMEDIATE THEREOF

PROBLEM TO BE SOLVED: To provide a drug molecule in a novel or purer polymorphic form. SOLUTION: In the present invention, disclosed is a novel p-toluenesulfonate of 1-((2S,5R)-5-((7H-pyrrolo [2,3-d] pyrimidin-4-yl) amino)-2-methyl piperidin-1-yl) prop-2-en-1-one and a crystalline polymorphic form 1 thereof, a pharmaceutical composition comprising the same, and their preparation and use. In the present invention, also disclosed is a novel phosphate of 1-((2S,5R)-5-((7H-pyrrolo [2,3-d] pyrimidin-4-yl) amino)-2-methyl piperidin-1-yl) prop-2-en-1-one, a pharmaceutical composition comprising the same, and their preparation and use. SELECTED DRAWING: Figure 1 COPYRIGHT: (C)2020,JPOandINPIT

Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans

Significant work has been dedicated to the discovery of JAK kinase inhibitors resulting in several compounds entering clinical development and two FDA approved NMEs. However, despite significant effort during the past 2 decades, identification of highly s